The product is a pharma-grade active pharmaceutical ingredient mixture composed of amoxicillin sodium and clavulanate potassium in defined mass ratios, supplied as a white to off-white hygroscopic powder for downstream manufacture of tablets, capsules, oral granules, and sterile injectable dry powders. Amoxicillin sodium has molecular formula C₁₆H₁₈N₃NaO₅S and molecular weight 387.4 g/mol; clavulanate potassium has molecular formula C₈H₈KNO₅ and molecular weight 237.3 g/mol. The sodium salt is selected for aqueous solubility sufficient to permit parenteral reconstitution, while potassium clavulanate is a mechanism-based β-lactamase inhibitor. The mixture is manufactured under current good manufacturing practice conditions and is intended to comply with the monograph and general chapter requirements of USP, Ph. Eur., and BP for amoxicillin/clavulanate dosage forms. It is not a finished product; the API supplier's certificate of analysis must be reviewed against the downstream manufacturer’s target finished-product specification and regional regulatory filing.

Chemical and Physical Specifications Governing the Drug Substance Mixture

Release control for this API pair focuses on assay, water content, related substances, pH, sterility, bacterial endotoxins, and particulate matter in reconstituted solution for injectable grades. The analytical separation is performed by reversed-phase HPLC because clavulanate potassium degrades to clavulanic acid and other β-lactam ring-opened impurities that must be separated from the amoxicillin sodium peak. System suitability requires resolution between amoxicillin and clavulanic acid of not less than 2.0 under the specified chromatographic conditions in USP <621>.

Water content is a critical in-process and release attribute because clavulanate potassium is hygroscopic and its solid-state stability is inversely correlated with headspace humidity. Packaging in aluminum foil with desiccant is required for storage at ≤25 °C and ≤60% RH; exposure to ambient moisture during dispensing or granulation must be limited to short durations or performed under low-dew-point air. Bulk and tapped density values for the milled mixture typically fall between 0.30 g/mL and 0.60 g/mL, with Carr index values from 20% to 35%, indicating poor-to-moderate flow as classified under USP <1174>. Particle size distribution measured by laser diffraction under Ph. Eur. 2.9.31 is often controlled as D90 ≤100 µm for tablet/capsule blends and may be tightened for oral granules or dry syrups to avoid coarse particles that impair suspendability.

Related substances are controlled by HPLC with limits for clavulanic acid, amoxicilloic acid, and dimeric clavulanate impurities. For injectable-grade material, the sum of specified and unspecified impurities is often set at ≤3.0% total, with any single unspecified impurity ≤0.5%. These thresholds align with the general framework of USP and Ph. Eur. monographs for β-lactam antibiotics. The pH of a 10% w/v aqueous solution of the sodium-containing mixture is typically 8.0 to 10.0; this alkaline pH supports dissolution but also accelerates clavulanate potassium hydrolysis after reconstitution. Injectable powders are therefore dissolved immediately before administration, and the reconstituted solution should be used within the in-use time specified in the product labeling, generally not exceeding 12–24 h at 2–8 °C.

In tableting and capsule filling, the moisture sensitivity of clavulanate potassium usually excludes aqueous wet granulation; dry granulation via roller compaction or slugging is preferred. The granulation step should maintain residual moisture at ≤1.5% w/w and use a low-humidity processing suite with dew point below -20 °C or relative humidity below 30% RH at 25 °C. Segregation of the two components is possible because of differences in particle size, bulk density, and electrostatic charge; blend uniformity testing follows USP <905> with acceptance value ≤15.0% for the low-dose clavulanate potassium component. During capsule filling, dosing discs or tamping pins require periodic verification because the hygroscopic powder can build up on contact surfaces and reduce fill weight consistency.

On rotary tablet presses, sticking of the hygroscopic powder to punch faces can occur when residual moisture exceeds 1.5% w/w; the corrective action is to reduce room dew point and increase punch polishing, not to add magnesium stearate above 1.0% w/w because excessive lubricant can delay disintegration. Dissolution testing by USP <711> apparatus II at 75 rpm in 900 mL of phosphate buffer pH 6.8 is used to verify that both actives release in a comparable profile. Amoxicillin sodium and clavulanate potassium differ in intrinsic dissolution rate; a formulation that releases amoxicillin rapidly can leave clavulanate potassium unprotected if the inhibitor dissolves too slowly, so dissolution profiles for both components are monitored simultaneously.

What Limits the Use of Aqueous Wet Granulation for This API Pair?

Aqueous wet granulation is restricted because clavulanate potassium is hydrolytically unstable in the presence of water; the β-lactam ring opens, yielding clavulanic acid and subsequent inactive degradation products. In wet massing, localized water activity at the powder surface is high, and drying cycles expose residual moisture to elevated temperatures. Published stability data and manufacturer technical bulletins indicate that the degradation rate accelerates with temperature and pH above 6.5, so aqueous processes require careful justification. If non-aqueous granulation is used, isopropanol or ethanol-based binder solutions are selected, but residual solvent limits in USP <467> must be met; the dryer exhaust and granulator seals must be rated for flammable solvents.

For injectable-grade powder, the moisture constraint is stricter because the reconstituted solution is sterile filtered or filled as a dry sterile powder after aseptic crystallization or lyophilization. The injectable product is exposed to USP <71> sterility testing and USP <85> bacterial endotoxin limits that are not required for oral-grade API. The dry sterile powder must reconstitute rapidly in water for injection without visible precipitates; particulate matter in the reconstituted solution is controlled by USP <788> limits for small-volume injections, with thresholds of ≤6000 particles/container at ≥10 µm and ≤600 particles/container at ≥25 µm.

Compared with amoxicillin trihydrate, the sodium salt carries a different hydration matrix and dissolution profile. Each gram of amoxicillin sodium contributes approximately 59.4 mg of sodium (2.58 mmol), a parameter that must be stated in the parenteral product labeling because sodium-restricted patients may receive multiple grams per day. Amoxicillin trihydrate is used for oral solid-dose manufacture but cannot provide rapid high-concentration parenteral solutions. When compared with other inhibitor combinations such as ampicillin/sulbactam or piperacillin/tazobactam, clavulanate potassium inhibits many class A β-lactamases, including TEM- and SHV-type enzymes, but is less reliable against chromosomal class C cephalosporinases. Sulbactam has lower inhibitory potency for some TEM variants, while tazobactam extends inhibition to selected class C enzymes; the clinical relevance of these differences is determined by CLSI M100 and EUCAST breakpoint tables for each species and site of infection.

When the Ratio Shifts From 2:1 to 7:1, Blend Uniformity Requirements Change

The product is supplied as a blend that can be formulated into common amoxicillin/clavulanate mass ratios of 2:1, 4:1, 5:1, and 7:1. The 5:1 ratio is typical for injectable vials delivering 500 mg/100 mg or 1000 mg/200 mg per vial. Oral tablet configurations include 250 mg/125 mg (2:1), 500 mg/125 mg (4:1), and 875 mg/125 mg (7:1). Oral suspension granules include 125 mg/31.25 mg per 5 mL (4:1) and 400 mg/57 mg per 5 mL (7:1). As the ratio increases, the proportion of clavulanate potassium falls, and the blend uniformity risk rises because the low-dose component must be distributed through a larger mass of amoxicillin sodium. Content uniformity testing for solid oral dosage forms follows USP <905>; for a 7:1 tablet, the clavulanate potassium component may require a finer particle size distribution or a two-stage dilution step to achieve acceptance value ≤15.0%.

The choice of ratio is not a potency adjustment only; it determines the exposure of the inhibitor relative to the time-dependent bactericidal activity of amoxicillin. In low-ratio products the inhibitor is present in higher mass, which may be necessary to protect amoxicillin against high-inoculum β-lactamase production. In high-ratio products such as 875 mg/125 mg, the inhibitor coverage may be adequate for susceptible organisms, but dose selection must follow regional antimicrobial susceptibility breakpoints and renal function adjustments. The drug product formulation also influences stability: film-coated tablets require core moisture below 2.0% w/w before coating, while dry syrup granules should be packed in bottles with molecular sieve desiccant to maintain clavulanate potassium potency throughout shelf life.

For oral granules and dry syrups, the API is blended with sucrose- or sorbitol-based diluents, suspending gums, and flavoring agents; the blend is filled by weight and reconstituted at the time of dispensing. The release testing for the finished granules includes water content, pH after reconstitution, viscosity of the suspension, and dose uniformity after resuspension. Manufacturer stress studies typically condition the unopened container at 40 °C and 75% RH for up to 6 months in accordance with ICH Q1A to generate stability-indicating data for clavulanate potassium, but published data for this specific configuration is limited beyond the approved product labels. The processing environment must remain below 60% RH during granule filling, and line clearances between batches are required because low-dose clavulanate potassium residues can contaminate subsequent products if cleaning protocols fail to remove the hygroscopic powder from contact surfaces.